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Introduction 
Aromatase Inhibitors (AI) are recommended for the adjuvant treatment of hormone receptor positive 
breast cancers in the post-menopausal population. These agents block the synthesis of oestrogen by 
inhibition of peripheral aromatase (1). Compared with Tamoxifen, third generation aromatase 
inhibitors have been shown to significantly improve disease free survival (DFS) (2-4), and include the 
steroidal inhibitor exemestane, and the nonsteroidal inhibitors, anastrozole and letrozole. In the 2013 
meta-analysis by Aydiner et al (5), five years of adjuvant therapy with aromatase inhibitors improved 
DFS (HR 0.89, p=0.001), and also overall survival (OS) (HR 0.92, p=0.046) when compared to tamoxifen. 
Aromatase inhibitors have also demonstrated improvement in DFS, OS and distant metastasis rate 
when sequenced with tamoxifen (HR 0.70, p<0.001; HR 0.81, p=0.003, HR 0.74, p<0.001 respectively), 
and an improvement in DFS as extended adjuvant treatment after 5 years of tamoxifen (HR 0.62, 
p=0.001) (5).  Recent evidence has revealed a benefit of continuing aromatase inhibitors for a period 
of 10 years, as reported in the MA.17R trial, which displayed significant improvement in breast cancer 
recurrence rates, and decreased contralateral breast cancer (6).   
 
Aromatase inhibitors are associated with joint and muscular symptoms, commonly referred to as 
aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) (7). AIMSS adversely impacts on 
the quality of life of many patients.  Studies recently investigating AIMSS have shown incidence of 
musculoskeletal symptoms to be as much as 50% (8-10), higher than the pivotal aromatase inhibitor 
trials with rates of approximately 20-35% (11-13). The prevalence of musculoskeletal symptoms 
impacts the long-term care of these patients. Analysis of longitudinal claims data from three American 
commercial health programs revealed sub-optimal adherence to anastrozole in 19-28% of patients in 
their first year of treatment (14). These statistics are consistent with other studies of aromatase 
inhibitor adherence (15-18), which report a significant percentage of patients displaying early 
discontinuation of treatment. There are important clinical implications of this data, as non-compliance 
with adjuvant endocrine therapies in early breast cancer has been shown to be detrimental to the 
patients’ survival (16). 
AIMSS usually presents as symmetrical pain or soreness in the hands, knees, hips, lower back, 
shoulders, and/or feet. It is often associated with early-morning stiffness and difficulty sleeping (19). 
There may be additional extra-articular symptoms present, such as myalgia, fibromyalgia, neuropathy 
and carpal tunnel syndrome (20). MRI studies conducted on patients taking aromatase inhibitors have 
shown the development of tenosynovial changes and increased intra-articular fluid in patients with 
AIMSS (7). Most of the symptoms will develop within the first two to three months of AI treatment 
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(19, 21). This systematic review aims to summarise the recent literature on the symptom management 
intervention strategies for AIMSS. Meta-analyses have been conducted where feasible.   
 
Methods 
Search Strategy 
A systematic search of the electronic literature was designed and conducted by an information 
specialist (KR) to identify the relevant evidence. The following databases were searched: PubMed, 
EMBASE, CINAHL and CENTRAL.  Controlled terminology (MESH, EMTREE, CINAHL headings) and free 
text words were used. Google scholar was also searched for unpublished literature. The final search 
of all the databases was conducted on 24th February 2016. Reference lists of relevant review articles 
and of the full text reviewed papers were also cross checked and any relevant papers included for 
review. The complete search strategies for all the databases can be found in Appendix 1.  
 
 Study Selection: Inclusion and Exclusion criteria 
Type of studies 
Although the best type of study to assess the efficacy of an intervention is a randomised controlled 
trial (RCT), the scope of studies for inclusion in this review has been expanded.  This is to reflect the 
recognition that there are very few RCT in the area, and to be inclusive of as many intervention types 
as possible to inform clinical practice and respond to patient enquiries.  Therefore, all clinical trials 
(prospective and retrospective), cohort and case control studies and preventative trials were 
considered. Conference abstracts were included, but where a later full paper has been published, the 
abstract was excluded and replaced with the full paper.  Letters to the editor detailing clinical trial 
results were also included. Conference abstracts and letters to the editor were only considered in the 
narrative analysis and were not included in the risk of bias assessment or meta-analysis as there was 
not enough information to make an accurate analysis. Case studies and small case series were 
excluded.  Papers detailing protocols only, as well as systematic reviews were excluded from the 
review, although these are considered in the discussion. Only papers published in English were 
considered.   
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Types of participants 
Women with stage I-III Breast Cancer on an adjuvant treatment with any aromatase inhibitor with, or 
at risk of, AIMSS were included.  AIMSS was defined as any new onset, or worsening, of any 
musculoskeletal symptom after commencement of an AI. Women with advanced/metastatic breast 
cancer (Stage IV) were excluded. Papers which did not clearly define the use of aromatase inhibitors 
distinct to other hormonal therapies were excluded, along with papers which included endocrine 
therapies other than aromatase inhibitors 
 
Types of intervention 
All types of symptom management interventions for AIMSS in this population were considered 
including – pharmacological, non-pharmacological and CAM (Complementary and Alternative 
Medicine).  
 
Types of outcome measures 
Primary outcomes and secondary outcomes included the improvement in AIMSS (pain, stiffness, 
mobility or functionality) from baseline, the improvement in persistence and compliance of patients 
continuing to take their aromatase inhibitor medication due to the intervention, the reduction in 
incidence of AIMSS, and the adverse events in relation to the intervention treating AIMSS symptoms. 
 
Data synthesis and analysis 
Where sufficient quantitative results were reported, meta-analysis was performed. I2 was used to 
measure heterogeneity between studies, as per the Cochrane handbook (22). An I2 value of 50-75% is 
defined as substantial heterogeneity and an I2 value of ≥75% is defined as considerable heterogeneity. 
Heterogeneity was expected between studies, and therefore a random-effects meta-analysis model 
was used for the meta-analyses. A separate meta-analysis was attempted for each sub-group of 
intervention. R programming software was used for the statistical analysis (23).  
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Methodological Quality 
RCTs were assessed using the Jadad Scale (24). Trials were deemed high quality studies if score 3-5, 
whilst score 0-2 was deemed low quality (25). Case control studies were assessed using the Newcastle-
Ottawa Scale, where a score of 7 to 9 indicates high methodological quality, a score of 4 to 6 indicates 
moderate quality and a score of 0 to 3 indicates low quality.  
 
Results 
Search results 
The search retrieved 1389 articles and after the removal of 458 duplicates, 931 remaining abstracts 
were screened, as shown in Figure 1. After 836 of these abstracts were excluded, 95 full text articles 
were assessed, with 38 meeting the inclusion criteria. 57 papers were excluded: In 17 studies the 
relevant outcomes were not covered; in 12 studies hormonal therapy was not distinguished as AI; in 
11 studies the abstracts were superseded by later full text papers; 10 papers were the wrong study 
design or publication type; 6 papers had the wrong patient setting; and 1 paper was not in English. 
 
Methodological Quality of Selected Studies 
Studies were unable to be assessed if they had only been published as an abstract, due to lack of 
available information. Out of 17 RCTs, only 11 could be adequately assessed for methodological 
quality, as the rest were only published in abstract form. Of the 11 assessable RCTs, eight studies had 
a high Jadad score ≥3 (26-33). Three studies scored poorly on the Jadad scale for methodological 
quality (34-36). Only six cohort studies had full-text available for assessment with the Newcastle 
Ottowa Scale. Of these six studies, two were assessed as high methodological quality (37, 38); two 
studies were median methodological quality (17, 39, 40); and one study was of poor methodological 
quality (41). 
 
Overall Characteristics of Selected Studies 
38 studies were included in the final analysis (see Table 1). These included 18 randomised control trials 
(RCTs)/ controlled clinical trials (CCT), 14 pre/post studies, and 6 cohort studies.  Studies were 
published between 2007 – 2016. The countries in which the studies were conducted include: United 
States (n=26), Japan (n=2), Spain (n=2), China (n=2), Canada (n=1), England (n=1), Australia (n=1), 
6 
 
Greece (n=1), France (n=1) and Italy (n=1). Of the trials which reported median ages of participants, 
the median age was 59.5 years (range 29-89). The scoring systems used across trials were extremely 
diverse, including Health Assessment Questionnaire (HAQ), Visual Analogue Scale (VAS), Brief Pain 
Inventory (BPI), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Modified 
Score for the assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH), Functional 
Assessment of Cancer Therapy – General (FACT-G), Arthritis Impact Measurement Scale (AIMS2), 
Medical Outcome Study Short Form 36 (SF 36), Pain self-efficacy questionnaire (PSEQ), OMERACT-
OARSI criteria, Disabilities of the Arm, Shoulder and Hand (DASH), AUStralian CANadian Osteoarthritis 
Hand Index (AUSCAN), Breast Cancer Prevention Trial – Musculoskeletal Symptom (BCPT-MS), 5 point 
Likert Scale, and the use of an electronic algometer and hand grip strength.  
The studies were analysed in four separate subgroups: Complementary Therapies; Acupuncture; 
Physical Therapies and Pharmacological Interventions.  
 
Analysis of Acupuncture Interventions 
Study Characteristics 
Six studies were included that investigated the use of acupuncture for AIMSS, involving 221 patients 
in total. There were five RCTs, three of which investigated the use of acupuncture (31, 32, 34) and two 
of which investigated the use of electro-acupuncture (28, 29). There was also one single-arm pilot 
study, which investigated the use of electroacupuncture (42). Of the RCTs, three studies investigated 
true acupuncture/electro-acupuncture versus sham acupuncture (28, 31, 32); one study had three 
arms consisting of true electro-acupuncture, sham electro-acupuncture and a waitlist control (29) and 
one trial was a crossover design, investigating acupuncture versus observation, then crossover after 
six weeks (34). The methods of sham acupuncture differed between trials, with some trials using sham, 
non-penetrating needles on real acupuncture points (28), and others using sham, non-penetrating 
needles at non-acupuncture, non-trigger points (29, 32). Crew et al (31), used superficial needle 
insertion at non-acupuncture points as the control.  The median sample size for the studies was 37 
(range 12 – 67). The primary outcome of all the studies included change in pain scores after the 
intervention. One study also listed primary outcomes as perceived benefit of acupuncture, hand 
strength and inflammatory markers (ESR and CRP) (28). 
Results 
In the two RCTs by Crew et al (31, 34), there was a reported benefit in the symptoms of AIMSS with 
the use of acupuncture. In the 2007 trial of 21 patients (34), patients underwent six weeks of 
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acupuncture followed by six weeks of observation, or vice versa. The mean BPI worst pain score at 
baseline was 5.3 compared with the mean BPI worst pain score after acupuncture of 3.3 (p=0.008). 
The benefits of acupuncture did not persist after six weeks of observation. In the 2010 RCT by Crew et 
al (31), 43 patients were randomised to either real or sham acupuncture for six weeks. There was a 
difference in pain scores at six weeks between true acupuncture and sham acupuncture arms, with 
mean BPI-SF worst pain scores 3.0 for true acupuncture versus 5.5 for sham acupuncture (p=0.002). 
Similar benefits were seen in pain severity (2.59 v 4.53; p<0.001) and pain-related interference (2.48 
v 4.54; p<0.002). No follow-up was performed after acupuncture cessation. In all the remaining RCTs 
investigating the use of acupuncture there was no statistical difference in pain outcomes between real 
and sham arms (28, 29, 32). In the trial by Bao et al (32), 47 patients were randomised to real or sham 
acupuncture for eight weeks. After eight weeks, there was no difference between treatment arms in 
either HAZ-DI scores (p=0.15) or VAS scores (p=0.31). Oh et al (28), investigated real versus sham 
electroacupuncture for six weeks of treatment in 32 patients. There was no difference between real 
and sham arms in regards to pain, function and stiffness using WOMAC scores, or pain severity and 
interference using BPI-SF scores. In the trial by Mao et al (29), 67 patients were enrolled into a three 
arm RCT, investigating real and sham electroacupuncture versus a waitlist control arm, for eight 
weeks. Both true electroacupuncture (EA) and sham electroacupuncture (SA) arms revealed a 
significant improvement in pain severity compared with the waitlist control arm (-2.0 vs -0.2, 
p=0.0004), but there was no difference between EA and SA arms.  
 
Two studies could be included in the method of meta-analysis, as they used the same scoring systems 
within their studies (29, 31). There was significant between-study heterogeneity for the effects of 
acupuncture on BPI-SF worst pain score (I2=79%). The overall mean difference in worst pain scores 
after acupuncture, using the random effects model was -0.98 (95% CI, -3.01 – 1.06).  
 
Analysis of Pharmacological Interventions 
Study Characteristics 
Twelve studies were included that investigated pharmacological interventions for the management of 
AIMSS, including 3 RCTs, 5 pre/post studies, and 4 cohort studies. Pharmacological therapies used 
were diverse, and included testosterone (43), etoricoxib (44), calcitonin (36), duloxetine (47), 
prednisolone (48), thymosin (49), bisphosphonates (40, 50), diuretics (41) and switching of aromatase 
inhibitor therapy (45, 46). There were 1407 patients analysed in total between all the pharmacological 
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trials, with a median sample size of 82.5 patients (range 16 – 316). The RCTs used a matched placebo 
in the control arms, and one of the retrospective cohort studies used controls from the ELPh Trial 
(Exemestane and Letrozole Pharmacogenetics Trial) (50). The other studies did not include a control 
arm. The primary outcome for majority of the studies was either the impact of the pharmacological 
intervention on musculoskeletal symptoms, or the prevention of musculoskeletal symptoms through 
use of the pharmacological intervention.  The study by Liu et al, had a primary outcome of the efficacy 
of calcitonin as therapy for osteoporosis in patients with bone pain during anastrozole therapy (36). 
In the study of switch therapy by Briot et al (46), the primary outcome was the percentage of women 
who discontinued letrozole secondary to musculoskeletal symptoms, after switching from 
anastrozole. Likewise, in the study of switch therapy by Kadakia et al, the primary outcome was 
tolerance of, and persistence with aromatase inhibitors (45). In the study of etoricoxib (44), the 
primary end-point was 5 years event free survival.  
Results 
Patients in all three RCTs experienced a reduction in pain, which was the primary outcome (36, 43, 
44). In the trial by Birrell et al (43), which has only been published as an abstract, 80mg testosterone 
resulted in a 70% decrease in Visual Analogue Scores (VAS) scores at 3 months, compared to only 35% 
decrease in VAS scores in the placebo arm (p=0.04). The third arm in this trial, testing 40mg 
testosterone, did not result in a substantial decrease in pain scores (p=0.06). The use of testosterone 
was not associated with a significant elevation in serum oestradiol. Rosati et al studied the use of 
etoricoxib (60mg/day) versus placebo, in addition to anastrozole (44). This study has also only been 
published as an abstract. During the trial, there was a U.S. Food and Drug Administration (FDA) alert 
on the use of etoricoxib and the potential risk for cardiovascular toxicity, resulting in a 38% 
discontinuation rate. Despite this, the incidence of musculoskeletal pain was still significantly higher 
in the placebo arm (RR 2.1, 95% CI 1.29 – 3.43, p=0.002). The third RCT, by Liu et al investigated 
calcitonin 200 IU/day plus caltrate D 600mg/day versus caltrate D alone for a period of three months 
(36). An improvement in pain scores, measured by VAS, was identified in both the placebo arm (score 
difference -1.00, p=0.0013) and intervention arm (score difference -3.00, p<0.0001). There was also 
notably a difference between the improvement in pain scores between the two arms (p<0.0001) (36).  
Analysis of Complementary Interventions  
Study Characteristics  
Ten studies were included that investigated the use of complementary therapies, including 6 RCTs, 2 
cohort studies and 2 pre/post studies. The interventions included Blue Citrus Herbal (51), omega-3-
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fatty-acids (O3FA) (30, 52), vitamin D (26, 27, 37, 39, 53) vitamin E (54) and glucosamine/chondroitin 
(55). The total number of patients investigated with complementary interventions was 403. The 
median sample size was 61 (range 31 – 209). All RCTs used a placebo as the comparator arm. The 
primary endpoint of majority of studies included the impact of the intervention on AIMSS. In the pilot 
study investigating O3FA, the primary outcome was feasibility (52), but the secondary outcome 
included patient-reported outcomes (PRO) of AIMSS. In the pre/post study of vitamin E, the primary 
outcome was the effect of vitamin E administration on female hormones and cytokines in patients 
experiencing AIMSS (54). Secondary outcomes included the effects of vitamin E on severity of AIMSS. 
In the vitamin D RCTs, the dosing of vitamin D in the intervention arms varied between studies, with 
interventions including 4000IU/day vitamin D3 (26); 50000IU vitamin D weekly (27); and 30000 IU 
vitamin D3 weekly (53).  
Results  
All three of the RCTs investigating the use of vitamin D (26, 27, 53), showed no benefit in the use of 
vitamin D for the management of AIMSS. The RCT investigating the use of Blue Citrus Herbal (51), 
which included 37 patients in the study, reported improvement in VAS pain scores with the use of Blue 
Citrus Herbal, but it was unclear if these improvements were statistically significant compared to the 
control arm. Some Blue Citrus herbal formulations can include up to 15 different herbs, including 
Curcuma (63). Caution is advised for usage of Curcuma in women with hormone sensitive conditions 
as theoretically it may exacerbate hormone sensitive breast, uterine or ovarian cancers (64). The 
specific formulation of the herb used in this trial is unclear. The two RCTs investigating the use of O3FA 
(30, 52) did not find any benefit of O3FA when compared to placebo. The larger of the O3FA RCTs, 
comprising 249 patients (30), reported a substantial improvement in AIMSS at 12 weeks in both the 
O3FA arm (BPI-SF score change -1.74, p<0.001) and the placebo arm (BPI-SF score change -1.50, 
p<0.001), but no significant difference between groups (p=0.38). These results were sustained at the 
24 week evaluation. The only positive result in the smaller O3FA RCT (52) was greater pain relief from 
medications in the O3FA arm at both 12 weeks (p=0.043) and 24 weeks (p=0.011).  
Analysis of Physical Therapy Interventions  
Characteristics of Studies  
Ten studies were included that investigated the use of physical therapies on the management of 
AIMSS, including 3 RCTs, 6 pre/post studies and a CCT. Three studies investigated a combined aerobic 
and resistance exercise program, including two randomised control trials (35, 56), and one pre/post 
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study (57). One pre/post study investigated a home-based exercise program (58), and two studies 
investigated walking programs, including one RCT involving Nordic Walking (33), and one pre/post 
study investigating a self-directed walking program (59). One pre/post study investigated Tai Chi (60), 
and two other pre/post studies investigated yoga (61, 62). A CCT investigated aquatic exercise (38). 
Therefore, the physical therapy interventions were extremely heterogeneous, ranging from two one 
hour tai chi sessions per week for 8 weeks (60), to 150 minutes of aerobic exercise weekly plus 
supervised strength training twice weekly (35). The mean sample size between studies was 31 patients 
(range 10-121). The total number of patients investigated in exercise trials was 313.  
 
Results  
Of the 3 RCTs, there was only one study showing benefit with physical therapy (35). The HOPE study, 
by Irwin et al, was the largest of the exercise studies in our analysis, with 121 participants (35). The 
study reported a 29% improvement in worst BPI scores in the exercise group at 12 months, as 
compared to a 3% increase in worst pain scores in the usual care group at 12 months (p<0.001) (35). 
The RCT by Fields investigating the use of Nordic walking versus waitlist control did not report any 
significant benefit in regards to AIMSS (33). The RCT by Lohrisch et al (56), closed early due to poor 
recruitment, and did not identify any significant benefit in the use of a mixed aerobic/resistance 
exercise program for the management of AIMSS.  
Two studies could be included in a meta-analysis of physical therapy interventions, as only two studies 
had the same pain scoring system within their studies, with available results (33, 35). There was 
significant between-study heterogeneity for the effects of physical therapy on BPI-SF worst pain score 
(I2=93%). The overall mean difference in worst pain scores after exercise intervention, using the 
random effects model was -0.29 (95% CI, -3.32 – 2.75). 
Discussion 
With the improving long-term prognosis for breast cancer patients, there is an increasing focus on 
survivorship, and the quality of life for breast cancer survivors. Despite the burden of AIMSS in the 
treatment of hormone receptor positive breast cancer, there is a paucity of large, well-designed trials 
to provide evidence on the management of this condition.  It should be emphasized that there is 
currently no standardised definition of AIMSS. The condition encompasses a broad range of 
symptoms, and therefore a standardised definition would not only assist trial design in the future, but 
also assist oncologists to recognise and manage this condition in the clinical setting.  
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In compiling this analysis, we identified a variety of factors which unfortunately compromise the 
quality of the available evidence. The majority of trials considered in this analysis included patients 
who either already experienced musculoskeletal symptoms which worsened after the initiation of an 
AI, or patients who developed new onset musculoskeletal symptoms after initiation of an AI.  
However, several trials which did not stipulate their inclusion requirement for AIMSS at entry. Poorly 
defined entry criteria may have resulted in some trials investigating long-standing musculoskeletal 
conditions, such as osteoarthritis, rather than AIMSS specifically. Furthermore, interventions with low 
perceived toxicity would be more likely to have uptake in patient groups with less severe symptoms 
leading to differences in patient groups between trials (65). The retrospective studies would have 
likely used physician-reported AIMSS and outcomes, whereas the most reliable process for reporting 
patient quality of life outcomes includes patient reported outcomes (PRO). (66) 
In the trials included in this analysis, a diverse range of scoring symptoms were used to record patient 
symptoms. Due to the heterogeneity of scoring systems used, it was difficult to compare the benefit 
of interventions between trials. The more simplistic scoring systems, such as VAS, may result in either 
overestimation or underestimation of the perceived benefit of an intervention. Multiple studies did 
not disclose their complete list of scoring results, which may indicate a risk of bias in the reporting of 
results.  
Our analysis included many studies investigating the management of AIMSS, but overall they provide 
poor quality evidence in this area. The majority of studies had small sample sizes and a high risk of 
inherent bias. As expected, it is extremely difficult to blind the intervention group in certain studies, 
and impossible to blind treatment arms in the physical therapy groups. The placebo effect has been 
found to be significant in other studies of pharmacological treatment of debilitating toxicities of cancer 
treatment (65, 67, 68). In addition, the choice of placebo or control arm may have contributed to some 
borderline results. Careful consideration should be given to the choice of placebo, as contamination 
may be a problem. For example, in one trial investigating the use of O3FA (30), soybean was used in 
the placebo tablet. It has been hypothesised that an oestrogenic component in soy may have impacted 
on the pain scores in the control arm. In a number of acupuncture trials, there was an improvement 
in pain scores in both the real acupuncture and sham acupuncture arms. It is theorised that sham 
acupuncture may  provide a therapeutic benefit by triggering the release of endorphins or activation 
of pain related neural matrix (69). Many of the acupuncture trials have gone to great lengths to 
attempt to eliminate the risk of bias from their study, but as expected, they have not been able to 
successfully blind their treatment arms to patients. This may have resulted in a bias of results 
stemming from positive patient expectations. Most of the studies also did not report trial participants’ 
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usage of other medications, including analgesia. There should be rigorous control for medications 
taken by trial participants, to prevent confounding variables affecting the trial outcome.  
There are a number of trials currently ongoing, with interventions such as duloxetine (NCT01598298), 
the interplay of pain, sleep quality and fatigue (NCT01983995), hypnosis (NCT02657993), testosterone 
(NCT01573442), acupuncture (NCT01535066), vitamin D (NCT01988090), and kinesiotaping 
(NCT02406794). Hopefully these trials will provide further evidence for the optimal management of 
AIMSS. 
 
Conclusion 
Suboptimal compliance with AI adjuvant therapy due to inadequately managed AIMSS remains a 
major unmet need in oncology practice. Patients who have failed to control AIMSS with over the 
counter analgesics may be willing to try other interventions, including complementary therapies, for 
symptom relief.  Many of these women have been financially impacted by their cancer and its 
treatment and some of the therapies discussed here may involve considerable financial commitment. 
Caution may also need to be advised if the CAM potentially contains oestrogenic compounds which 
may explain the mechanism of action and which theoretically could compromise breast cancer 
survival. Pharmacological treatment is often recommended by health professionals for AIMSS, 
however in conclusion, there is limited published evidence for its use. Exercise showed benefit in a 
single RCT (35), but the other studies showed little evidence of benefit. Information from the meta-
analysis is limited by inclusion of only two studies with opposing results. The evidence for acupuncture 
is not strong enough to recommend it for the treatment of AIMSS. Although the interventions 
generally appear tolerable with minimal adverse effects, the current level of evidence is low, and 
additional large RCTs with more rigorous control for contamination from other interventions are 
required to confirm some of the reported promising results.  
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APPENDIX 1 
PubMed  
 
1."Aromatase Inhibitors"[Mesh]  
2. "exemestane"[Supplementary Concept])  
3. "letrozole"[Supplementary Concept])  
4. "Aminoglutethimide"[Mesh])  
5."atamestane"[Supplementary Concept])  
6. "Fadrozole"[Mesh])  
7. "formestane"[Supplementary Concept])  
8. "vorozole"[Supplementary Concept])  
9. "aromatase inhibitor"  
10. "aromatase inhibitors"  
11. anastrozole  
12. arimidex  
13. exemestane  
14. letrozole  
15. aromasin  
16. femara  
17. fadrozole  
18. formestane  
19. lentaron  
20. vorozole  
21. rivizor  
22. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
OR #16 OR #17 OR #18 OR #19 OR #20 OR #21  
23. "Musculoskeletal Diseases"[Mesh])  
24. "Pain"[Mesh]  
25. "Pain Measurement"[Mesh]  
26. "Carpal Tunnel Syndrome"[Mesh])  
27. musculoskeletal OR musculo-skeletal  
28. (joint* OR hand OR hands OR elbow* OR knee* OR wrist*) AND (pain* OR discomfort* OR tender* 
OR stiff*)  
29. tendinitis  
30. tendinopath*  
31. tenosynovitis  
32. arthralg*  
33. rheumat*  
34. "trigger finger"  
35. "carpal tunnel syndrome"  
36. fibromyalg*  
37. myalg*  
38. #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 
OR #36 OR #37  
39. "Postmenopause"[Mesh]  
40. “Breast Neoplasms"[Mesh]  
41. breast AND (cancer OR cancers OR carcinoma* OR malignan* OR tumor OR tumors OR tumour*)  
42. #39 OR #40 OR #41  
43. Clinical[Title/Abstract]) AND Trial*[Title/Abstract]  
44. "Clinical Trials as Topic"[Mesh]  
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45. "Clinical Trial" [Publication Type]  
46. random*[Title/Abstract]  
47. "Prospective Studies"[Mesh]  
48. “Follow-Up Studies"[Mesh]  
49. "Feasibility Studies"[Mesh]  
50. pilot[Title/Abstract]  
51. prospective[Title/Abstract]  
52. #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51  
53. #22 AND #38 AND #42 AND #52  
 
EMBASE  
 
1. aromatase NEAR/2 inhibit*  
2. 'aromatase inhibitor'/exp  
3. anastrozole  
4. exemestane  
5. 'letrozole'  
6. aminoglutethimide*  
7. atamestane  
8. formestane  
9. vorozole  
10. arimidex  
11. aromasin  
12. femara  
13. fadrozole  
14. lentaron  
15. rivizor  
16. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12 OR #13 OR #14 OR #15  
17. 'breast cancer'/exp  
18. breast NEAR/3 (cancer* OR carcinoma* OR malignan* OR tumo*r*)  
19. #17 OR #18  
20. 'clinical trial'/exp  
21. 'feasibility study'/exp  
22. `pilot study'/exp OR  
23. 'prevention study'/exp  
24. 'comparative study'/exp  
25. 'intervention study'/exp  
26. 'prospective study'/exp  
27. random*:ab,ti  
28. (clinical:ab,ti AND trial:ab,ti)  
29. pilot*:ab,ti  
30. prospective:ab,ti  
31. group*:ab,ti  
32. feasability:ab,ti  
33. controlled:ab,ti  
34. #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 26 OR #27 OR #28  
OR #29 OR #30 OR #31 OR #32 OR #33  
35. 'pain measurement'/exp  
36. 'pain assessment'/exp  
37. musculo*skeletal:ab,ti  
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38. arthralg*:ab,ti  
39. 'carpal tunnel syndrome':ab,ti  
40. 'trigger finger':ab,ti  
41. tendin*:ab,ti  
42. myalg*:ab,ti  
43. fibromyalg*:ab,ti  
44. tenosynov*:ab,ti  
45. ((joint* OR muscl* OR hand* OR knee* OR hip* OR shoulder* OR feet OR foot OR elbow*) 
NEAR/3 (pain* OR stiff* OR sore* OR discomfort* OR symptom*)):ab,ti  
46. 'morning stiffness'/exp  
47. 'musculoskeletal stiffness'/exp  
48. 'musculoskeletal disease'/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
49. 'arthropathy'/exp/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm-_pc  
50. 'pain'/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
51. 'arm pain'/de  
52. OR 'hand pain'/de  
53. 'leg pain'/exp/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
54. 'limb pain'/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
55. 'limb pain'/de OR  
56. 'myalgia'/exp/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
57. 'neuralgia'/exp/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
58. 'shoulder pain'/dm_su,dm_dt,dm_th,dm_rh,dm_dm,dm_pc  
59. 'wrist pain'/de  
60. #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR 
#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR 
#59  
61. #16 AND #19 AND #34 AND #60  
 
 
CENTRAL  
 
#1  MeSH descriptor: [Aromatase Inhibitors] explode all trees  
#2 aromatase inhibit* (Word variations have been searched)  
#3 anastrozole or exemestane or letrozole or aminoglutethimide* or ata 
mestane or fadrozole or formestane or vorozole or arimidex or aromasin or femara or 
fadrozole or lentaron or rivizor (Word variations have been searched)  
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Breast Neoplasms] explode all trees  
#6 breast near cancer  
#7 breast near (tumour or tumor)  
#8 breast near malignan*  
#9 breast near carcinoma  
#10  #6 or #7 or #8 or #9  
#11  MeSH descriptor: [Musculoskeletal Diseases] 1 tree(s) exploded  
#12  myalg*  
#13  fibromyalg*  
#14  arthropath*  
#15  (joint or muscl* or arm* or leg* or shoulder* or elbow* or knee* or hip* or hand* or feet or 
foot)  
#16  (pain* or stiff* or sore* or discomfort* or symptom*)  
#17  #15 near #16  
16 
 
#18  tendin*  
#19  (musculoskeletal or musculo-skeletal)  
#20  "trigger finger" or "carpal tunnel"  
#21  tenosynov*  
#22  #12 or #13 or #14 or #17 or #18 or #19 or #20 or #21  
#23  #11 or #22  
#24  #4 and #10 and #23 in Trials  
 
 
CINAHL   
 
1. (MH "Aromatase Inhibitors+")  
2. TX (aromatase N3 inhibit*)  
3. TX exemestane  
4. TX letrozole  
5. TX aminoglutethimide*  
6. TX atamestane  
7. TX fadrozole  
8. TX formestane  
9. TX vorozole  
10. TX arimidex  
11. TX aromasin  
12. TX femara  
13. TX fadrozole  
14. (TX hormon* W1 therap*)  
15. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12 OR #13 OR #14  
16. ((TX (joint* OR muscl* OR hand* OR knee* OR hip* OR shoulder* OR feet OR foot OR elbow* 
OR rheumat* OR arthrit*) N4 TX (pain* OR stiff* OR discomfort* OR symptom* OR mobil*))  
17. (MH "Treatment Related Pain")  
18. (MH "Pain Measurement")  
19. (MH "Pain+")  
20. (MH "Knee Pain+")  
21. (MH "Metatarsalgia")  
22. (MH "Muscle Pain")  
23. (MH "Arthralgia+")  
24. (MH "Shoulder Pain")  
25. (MH "Musculoskeletal Diseases")  
26. (MH "Foot Diseases+")  
27. (MH "Joint Diseases+")  
28. (MH "Muscular Diseases+")  
29. (MH "Rheumatic Diseases+")  
30. TX musculo#skeletal  
31. TX arthralg*  
32. TX myalg*  
33. TX tendin*  
34. TX fibromyalg*  
35. TX tenosynov*  
36. TX "trigger finger"  
37. TX "carpal tunnel"  
38. (MH "Joints+")  
17 
 
39. (MH "Pain Threshold")  
40. (MH "Range of Motion")  
41. #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR 
#28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR 
#40  
42. (MH "Breast Neoplasms") OR (MH "Carcinoma, Ductal, Breast") OR (MH "Hereditary Breast 
and Ovarian Cancer Syndrome"))  
43. (TX(breast N3 (cancer* OR carcinoma* OR malignan* OR tumo#r*))))  
44. ((MH "Cancer Survivors")))  
45. #42 OR #43 OR #44  
46. #15 AND #41 AND #45 
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Figure 1: PRISMA FLOW CHART  
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Figure 2: Effect of acupuncture on AIMSS using BPI-SF. SD, standard deviation; MD, mean difference; 
CI, confidence interval.  
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Figure 3: Effect of physical therapy on AIMSS using BPI-SF. SD, standard deviation; MD, mean 
difference; CI confidence interval.  
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Table 1: All included studies in the analysis  
 
Intervention & 
Author 
Type n Arms Significant Outcome 
Acupuncture 
Acupuncture 
Bao 2013 (32) 
 
RCT 51 Real vs Sham (8 weeks) No. Similar VAS scores at 8 weeks between real 
and sham arms (p 0.31) 
Acupuncture 
Crew 2007(34) 
RCT 21 Real (RA) vs Sham (SA)  
6 weeks then crossover 
Yes, RA better at 6 weeks (values not given). Not 
sustained 12 weeks 
Acupuncture  
Crew 2010 (31)  
RCT 38 Real vs Sham (6 weeks) Yes. Worst pain 3 vs 5.5  
(p<0.001) at 6 weeks 
Electroacupuncture 
Oh 2013 (28) 
RCT 32 Real vs Sham (6 weeks) No. No difference in pain between groups (no 
values given) 
Electroacupuncture 
Mao 2014 (29)  
RCT 67 Real vs Sham vs waitlist (8 
weeks) 
Yes. Decrease in pain severity in EA (-2.2) vs WLC 
(-0.2, p=0.0004), week 8. Benefits continue 
week 12.  
Electroacupuncture 
Mao 2009 (42) 
Pre/post 12 6 weeks Yes. Decrease in pain severity (5.3 to 1.9; 
p<0.001)  
Pharmacological 
Testosterone 
Birrell 2010 (43) 
RCT 90 Placebo vs 40mg vs 80mg 
daily 
Yes. VAS score decreased 70% in 80mg arm, 
compared to 35% decrease in placebo arm 
(p=0.04) 
Etoricoxib 
Rosati 2011 (44) 
RCT 182 Etoricoxib 60mg/day vs 
placebo 
Yes. Improved pain. 31% MSS symptoms vs 76% 
(RR 2.1 p=0.002) 
Calcitonin 
Liu 2014 (36) 
RCT 82 200IU/day salmon calcitonin 
daily 
Yes. Improvement in VAS scores in both groups 
(placebo -1.00; calcitonin -3.00). Difference 
between groups p<0.01.  
Switch 
Kadakia 2016 (45) 
Pre/post 83 Exemestane or letrozole; 
crossover if intolerant 
62% continued second aromatase inhibitor at 6 
months.  
Switch  
Briot 2010 (46)  
Pre/post 179 Anastrozole switched to 
letrozole 
Yes. 19% decrease pain scores (p<0.001) 
72% continued letrozole 6 months. 
Duloxetine 
Henry 2011 (47)  
Pre/post 29 30mg 7 days, then 60mg 21 
days, then 60mg bid  
Yes. Mean decrease pain severity 60% (p<0.001; 
95% CI 49-73%) 
Prednisolone 
Kubo 2012 (48) 
pre/post 27 5mg prednisolone for 1 
week.  
Yes. 52% reported improved VAS at 2 months 
post prednisolone use.  
No p-values given 
Thymosin 
Zhang 2010 (49) 
Pre/post 16 Thymosin α1 1.6mg twice 
weekly for 4 weeks 
Yes. Decreased BPI worst pain scores (5.7-3.4, 
p<0.001) 
Bisphosphonates 
Santa Maria 2014 (50) 
Cohort 59 Zoledronic acid 4mg baseline 
and 6 months 
Yes. 37% on zoledronic acid had AIMSS, compare 
to 61% in historical cohort (p<0.001) 
Bisphosphonates 
Muslimani 2009 (40) 
Retrospective 
Cohort  
316 Calcium and Bisphosphonate 
vs none 
Yes. Associated between AIMSS symptoms and 
low bone mineral density (p<0.001) 
Diuretic Therapy 
Xepapadakis 2010 (41) 
Retrospective 
Cohort 
288 Diuretic therapy vs no 
diuretics 
Yes. 7% on diuretics had arthralgia, compared 
with 16% not on diuretics (p0.01) 
Analgesics/ supplements 
Presant 2007 (17) 
Retrospective 
Cohort 
56 Chart review pain meds and 
effectiveness 
50% obtained relief from NSAIDs 
Complementary Therapies 
Blue Citrus Herbal (BCH) 
Massimino 2011 (51) 
RCT 31 BCH vs Placebo (P) then 
crossover 
90 days each 
Yes. Both arms experienced decreased VAS 
(p<0.02). No p value given for BCH vs P 
O3FA 
Herschmann 2015 (30) 
RCT 249 O3FA vs placebo  
24 weeks 
Yes. Improved BPI worst pain in O3FA arm (-
2.23, p<0.001) and placebo arm (-1.81, 
p<0.001). No difference between arms (p=0.52) 
O3FA 
Lustberg 2014 (52) 
RCT 44 O3FA vs placebo  
24 weeks 
No difference in mean BPI-SF pain scores. Less 
interference of pain in O3FA arm (-0.72, p=0.08) 
Vitamin D 
Khan 2012 (53) 
RCT 160 30000IU D3wkly vs placebo 
for 24 weeks 
No. 51% in placebo arm vs 37% in vitamin D arm 
had MS event (p=0.069) 
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Vitamin D 
Rastelli 2011  (27) 
RCT 60 Vit D2 50000IU vs placebo 
weekly 8-16 weeks then 
mthly for 4 months 
Benefit in BPI worst pain in Vit D arm at 2 
months (p=0.0045).  
No difference between groups in regards to pain 
at 4 or 6 months. 
Vitamin D 
Shapiro 2016  (26) 
RCT 113 600 IU Vit D3 vs 4000 IU Vit 
D3 daily for 6 months 
No. Change in BCPT-MS scores at 6 months: -0.5 
in 600IU D3 vs -0.2 in 4000 IU D3, p=0.38 
Vitamin D 
Khan 2010  (39) 
Cohort 51 Vit D3 50000IU weekly for 12 
weeks  if 25OHD <40ng/ml vs 
standard D3/Calcium  
Yes. Difference in pain between Vit D <66ng/ml 
(52%) vs > 66ng/ml (19%; p=0.026).  
Vitamin D 
Prieto-Alhambra 2011 
(37) 
Cohort 290 16000 IU Vit D3 q2wkly if 
25(0H)D <30ng/ml vs Vit D3 
800 IU daily 
Joint pain less likely if 25(OH)D >40ng/ml 
(p<0.008). VAS scores increased in entire cohort 
(p<0.001) 
Vitamin E 
Kiyomi 2015 (54) 
Pre/post 62 Vit E (150mg/day) for 30 
days 
Yes. Mean osteoarthropathy scores (scoring 0-3) 
improved with Vitamin E (p=0.0178) 
Glucosamine/ 
chondroitin 
Greenlee 2013 (55) 
Pre/post 37 Glucosamine (1500mg) + 
chondroitin (1200mg) daily. 
24 weeks 
Yes. Benefit in BPI worst pain (-1.2, p=0.02); M-
SACRAH pain (-13.8, p=0.0008) & WOMAC pain 
(-10.7, p=0.02).  
Physical Therapies 
Aerobic/Resistance 
Irwin 2015 (35) 
RCT 121 12/12 supervised vs usual 
care 
Yes. Decreased pain by 1.6 points vs 0.2 points 
(p<0.001) 
Aerobic/Resistance 
Lohrisch 2011 (56) 
RCT 20 48/52. Step-down 
supervision vs UC 
No. No difference between groups. No p values 
given for results.  
Aerobic/Resistance 
Lash 2011 (57) 
Pre/post 14 Supervised, 2-3 times/week, 
8/52 
Yes. Pain in multiple joints decreased (p<0.05). 
Scores not given.  
Aerobic/Resistance 
DeNysschen 2013 (58) 
Pre/post 26 8/52 home-based exercise Yes. Improvement in pain by AIMS2, 
-2.7 (p=0.01).  
Aquatic 
Cantarero-Villanueva 
2012 (38) 
CCT 40 2/12 hydrotherapy vs 
waitlist  
Yes. Improved pressure pain threshold in 
treatment arm (p<0.05). No benefit in waitlist 
arm.  
Nordic Walking 
Fields 2015 (33) 
RCT 40 6/52 supervised followed by 
6/52 self-managed walking 
vs waitlist control 
No. Pain scores changed -1.1 Nordic walking vs -
2.4 control group (p=0.10) 
Walking 
Nyrop 2014 (59) 
Pre/post 20 Self-directed walking 
program, 6/52 
No. Mean joint pain decreased 10% (p0.63) 
Tai Chi 
Galantino 2013 (60) 
Pre/post 12 Supervised tai chi, 8/52 No. Difference in pain severity -1.04 (p=0.058) 
Yoga 
Jacobsen 2015 (61) 
Pre/post 10 Supervised yoga, 12/52 Yes. Improved BPI pain severity -1.35 (p=0.015) 
Yoga 
Galantino 2012 (62)  
Pre/post 10 Supervised, 8/52 Yes. BPI pain severity reduced (3.90 to 2.79; 
p<0.05)  
VAS = visual analogue scale, EA = electroacupuncture, WLC = waitlist control, MSS = musculoskeletal symptoms, Vit = vitamin, 
BPI = brief pain inventory, AIMSS = Aromatase inhibitor-induced musculoskeletal symptoms, NSAIDs = non-steroidal anti-
inflammatory drugs, O3FA = omega 3 fatty acids, BPI-SF = brief pain inventory, short-form, BCPT-MS = Breast Cancer 
Prevention Trial-Musculoskeletal Symptoms subscale,  M-SACRAH = Modified Score for the assessment of Chronic Rheumatoid 
Affections of the Hands, WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index, AIMS2 = Arthritis Impact 
Measurement Scale 
 
